FDA Approves First Targeted Treatment for Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Have a Certain Genetic Mutation.
The U.S. Food and Drug Administration today approved Tibsovo (ivosidenib) tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. This is the first drug in its class (IDH1 inhibitors) and is approved for use with an FDA-approved companion diagnostic used to detect specific […]
